Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2013

View Archived Issues

New antiviral agents prepared by GlaxoSmithKline

Jazz Pharmaceuticals announces licensing agreement

Vertex begins pivotal phase III lumacaftor/ivacaftor study

Ampio Pharmaceuticals begins Optina trial in diabetic macular edema

Inviragen advances DENVax into second stage of phase II trial

Lupin prepares new agents for HCV infection

SB-010 proves to be well tolerated in three distinct phase I trials

Takeda and Resolve Therapeutics enter partnership

Team describes methods to derive toolboxes of macrocyclic compounds

Vildagliptin approval expanded in Japan

Biosimilar of filgrastim approved in Japan

Novel coagulation factor XIa inhibitors patented by Bristol-Myers Squibb

Dainippon Sumitomo Pharma obtains additional indication approval for Surepost in Japan

HanAll BioPharma presents new AMPK activators

QRx Pharma resubmits MoxDuo NDA to the FDA

Ventana and Biocare Medical sign license agreement for diagnosis of prostate lesions

Burkholderia mallei mutant shows promise as a live attenuated vaccine

Korean group prepares novel 11-beta-HSD-1 inhibitors

ViiV Healthcare grants voluntary license to increase access to HIV medicine for children

Ceptaris resubmits NDA for proprietary gel formulation of chemotherapeutic agent

Immune response to intradermal flu vaccine evaluated in patients with atopic dermatitis

Sylentis commences phase II trial with SYL-1001

European Commission approves Ilaris in acute gouty arthritis indication

FDA approves once-monthly intramuscular depot formulation of aripiprazole

Hyperion's Ravicti now available in U.S.

Lundbeck's Selincro approved in E.U. for alcohol dependence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...